This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia (ADVANCE-II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03697707
Recruitment Status : Active, not recruiting
First Posted : October 5, 2018
Last Update Posted : October 10, 2022
Amsterdam UMC, location VUmc
Information provided by (Responsible Party):

Brief Summary:
Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia in Remission Biological: DCP-001 Phase 2

Detailed Description:
International, multicentre, open-label proof of concept study exploring two different dose groups of the allogeneic dendritic cell vaccine, DCP-001. Cohort 1 consists of 10 patients that will receive 25E6 DCP-001 cells per vaccination and Cohort 2 consists of 10 patients who will receive 50E6 DCP-001 cells per vaccination. All patients will be given two additional booster vaccinations of 10E6 cells. Each patient will be followed up for 12 months after the 4th vaccination. Safety will be monitored throughout the study. Sera and cell samples (blood and bone marrow) will be collected for assessment of efficacy (MRD evaluation) and immune response monitoring.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: First 10 patients will get the lowest dose and next 10 patients will receive the highest dose
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD
Actual Study Start Date : October 15, 2018
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : December 2025

Arm Intervention/treatment
Experimental: Cohort 1: Low dose
patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
Biological: DCP-001
allogeneic dendritic cell vaccine

Experimental: Cohort 2: High dose
patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
Biological: DCP-001
allogeneic dendritic cell vaccine

Primary Outcome Measures :
  1. minimal residual disease (MRD) [ Time Frame: up to 32 weeks ]
    Any change in MRD (flow cytometric) as compared to baseline MRD

Secondary Outcome Measures :
  1. Treatment emergent adverse events (TEAEs) [ Time Frame: up to 56 weeks ]
    adverse event

  2. Serious Adverse Events (SAEs) [ Time Frame: up to 56 weeks ]
    adverse events

  3. Relapse-free survival [ Time Frame: up to 56 weeks ]

  4. Overall survival [ Time Frame: up to 56 weeks ]

  5. Immune responses [ Time Frame: up to 32 weeks ]
    Any change in immunoreactivity (specific and non-specific) as compared to baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Confirmed diagnosis of AML according to WHO2016 criteria, including cytological, molecular and cytogenetic criteria (except acute pro-myelocytic leukaemia/APL).
  2. In CR1 (first complete remission) or CRi (incomplete blood count recovery) documented by bone marrow examination up to one month before vaccination; CR defined as less than 5% blasts in normo-cellular bone marrow, ANC >1*E9/L, platelet count >100*E9/L, no evidence of extra-medullary disease. Patients in CRi (patients with <5% blasts but with incomplete blood count recovery) should have platelets >50 E9/L.
  3. MRD as defined by multicolour flow cytometry (MFC) at a value of > 0.1%, or detection of specific molecular abnormalities such as NPM1 mutation.
  4. Patients that are in CR1 or CRi. Patients not having undergone consolidation therapy must have been in CR1 for at least 1 month prior to enrolment. Patients treated with hypomethylating agents must have been given at least two cycles and up to a maximum of nine cycles of hypomethylating agents.
  5. Expected and willing to undergo all study procedures, including outpatient evaluations for clinical and immunological monitoring.
  6. Male or female of ≥ 18 years of age.
  7. Women of childbearing potential must be using anti-conceptive therapy or use two (2) barrier contraceptive methods (one by each partner and at least one of the barrier methods must include spermicide (unless spermicide is not approved in the country or region). See section 12.7 for birth control methods deemed acceptable for this study.
  8. ECOG (WHO) performance status 0-2.
  9. Willing and able to provide written informed consent for participation in the study

Exclusion Criteria:

  1. Acute Promyelocytic (APL; M3) type of AML.
  2. Patients who have undergone or are scheduled/eligible for allogeneic stem cell transplantation.
  3. History of previous allogeneic bone marrow or solid organ transplantation.
  4. Uncontrolled or serious infections
  5. Ongoing immunosuppressive therapy, other than short use of low dose steroids, i.e. equivalent to an average dose of ≤10mg of prednisone/day.
  6. Chemotherapy and antineoplastic hormonal therapy within 28 days prior to the screening visit, with the exception of hypomethylating agents such as azacitidine and decitabine, or midostaurin for FLT3 mutations, or patients treated with IDH12 inhibitors in mIDH1/2.
  7. Current or past medical history autoimmune disease.
  8. Inadequate liver function (AST and ALT > 3 x ULN, serum bilirubin >3 x ULN).
  9. Other active Malignancies within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin or adequately controlled limited basal cell skin cancer.
  10. Pregnant or lactating females.
  11. Major surgical procedure (including open biopsy) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
  12. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (i.e. active) cardiovascular disease.
  13. Evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
  14. Known HIV, Hepatitis B and/or Hepatitis C infections.
  15. History of hypersensitivity to the investigational medicinal product or to any excipient present in the pharmaceutical form of the investigational medicinal product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03697707

Layout table for location information
Helsinki University Hospital
Helsinki, Finland
Universitats Klinikum Bonn
Bonn, Germany
Marien Hospital
Düsseldorf, Germany, D- 40479
Universitats Klinikum Leipzig
Leipzig, Germany
Universitätsmedizin Mainz
Mainz, Germany
Amsterdam, Netherlands
Groningen, Netherlands
Maastricht University Medical Centre
Maastricht, Netherlands
Haukeland universitetssjukehus
Bergen, Norway
Uppsala University Hospital
Uppsala, Sweden
Sponsors and Collaborators
Amsterdam UMC, location VUmc
Layout table for investigator information
Principal Investigator: A A van de Loosdrecht, MD, PhD Amsterdam UMC, location VUmc
Layout table for additonal information
Responsible Party: Mendus Identifier: NCT03697707    
Other Study ID Numbers: DCOne-002
First Posted: October 5, 2018    Key Record Dates
Last Update Posted: October 10, 2022
Last Verified: October 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mendus:
AML in CR1 or CRi
Minimal Residual Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type